CA
NZ
UK
AU
IND
US
On a non-GAAP basis, gross margin was 56%, operating income was USD 3.9 billion for a 29% margin versus 24%, and net income was USD 3.5 billion. Non-GAAP diluted EPS of USD 2.09 compared with USD 1.66 in the second quarter. Chair and Chief …
GAAP EPS increased 19% from USD 5.93 to USD 7.08.GAAPOperating Incomerose from USD 2.5 billion to USD 3.7 billion, lifting GAAPOperating Marginby 9.9 percentage points to 37.5%. Non-GAAP EPS rose 14% from USD 5.64 to USD 6.45, with non-GAAP operating income of USD 4.7 …
Platform subscription revenue was USD 23.9 million versus USD 30.9 million. Visits revenue was USD 23.7 million versus USD 21.2 million, and other revenue was USD 1.4 million versus USD 4.2 million.
President and Chief Executive Officer Bill Krueger said results improved in both Renewables and Agribusiness. For the first nine months, net income attributable to the company was USD 136.2 million versus USD 28.3 million, and adjusted EBITDA was USD 333.1 million versus USD 200.7 …
GAAP operating margin was 44.9% against 42.4%, and non-GAAP operating margin was 49.1% against 48.6%. Chairperson and Chief Executive Officer Jayshree Ullal described record profitability that surpassed her own high expectations, and the chief financial officer called the quarter a trifecta of record revenue …
Selling andMarketingexpense was USD 127.0 million versus USD 129.3 million, and general and administrative expense was USD 62.0 million versus USD 69.4 million. Product development expense was USD 9.3 million versus USD 20.7 million.
Manufacture and supply revenue was USD 6,659 thousand versus USD 11,467 thousand. License andRoyaltyrevenue was USD 824 thousand versus USD 1,038 thousand, and co-development and research fees were USD 74 thousand versus USD 302 thousand.
Product sales, net, were USD 125,455 thousand versus USD 105,515 thousand. ProductSupplyRevenuewas USD 1,380 thousand, with none in the prior-year quarter. Licensing revenue was USD 216 thousand versus USD 25 thousand, and non-cashRoyaltyrevenue related to the sale of future royalties was USD 604 thousand …
Adjusted EBITDA was USD 121 million, up 2%. Growth in Life Sciences, Personal Care and Intermediates was partly offset by lowerEarningsin Specialty Additives. Average diluted shares outstanding were 46 million, unchanged from the prior-year quarter.
Gross profit was USD 119.4 million compared with USD 101.3 million, and gross margin of 77.3% was 180 basis points higher on favorable product and geographic mix. Income from operations was USD 4.4 million versus USD 0.2 million, and net income was USD 4.1 …
Please wait processing your request...